PRNEWSWIRE
ASH 2022 | Ascentage Pharma to Present Initial Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Combination with BTK Inhibitors for the Treatment of R/R CLL/SLL, Including an ORR of 98%, in an Oral Report at the ASH Annual Meeting
2022-11-03
ASH 2022 | Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, at the ASH Annual Meeting
2022-11-03
RemeGen Releases Phase II Clinical Study Data for Treatment of Myasthenia Gravis in Chinese Patients
2022-11-01
GenScript Supported Nasal Spray Development for COVID-19 Protection with GMP-grade Antibodies and Subsequently Planned for Long-Term Collaboration with Biogenexis
2022-10-31
Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors
2022-10-31
NDA for New Second-Line Indication of CAR T-Cell Therapy Product YIKAIDA (Axicabtagene Ciloleucel Injection) Approved for CDE Review
2022-10-27
OncoK9®, the Pioneering Blood-Based Early Cancer Detection Test for Dogs, Now Available in Asia Through Asia Veterinary Diagnostics
2022-10-26
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting
2022-10-26
ImmVira announced its signing of Series C+ financing and negotiation with further investors for the round
2022-10-26
Metabolon Advances the Understanding of Inflammation and Inflammatory Response with New Oxysterols Targeted Panel
2022-10-25
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02